Noninvasive bioluminescent and microPET imaging for the regulation of NF-κB in human hepatoma-bearing mice

Anticancer Research

Volumn 29, Issue 4, 2009, Pages 987-994

  Chang, Tsui Jung ^a   Chang, Ya Jen ^a   Ho, Tin Yun ^b   Hsiang, Chien Yun ^b   Yu, Chia Yu ^a   Lee, Te Wei ^a   Lin, Wu Jyh ^a   Chang, Chih Hsien ^a  

^a INSTITUTE OF NUCLEAR ENERGY RESEARCH   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Bioluminescentimaging,18F fluorodeoxyglucose,; luciferase,micropositron emissiontomography(microPET),; nuclearfactor B

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LUCIFERASE; METHOTREXATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLUMINESCENCE; CELL STRAIN HEPG2; CELL TRANSFORMATION; FEMALE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MOLECULAR CLONING; MOLECULAR IMAGING; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCID MOUSE; TUMOR PROMOTION;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOGENS; DIAGNOSTIC IMAGING; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LIVER NEOPLASMS, EXPERIMENTAL; LUCIFERASES; LUMINESCENT MEASUREMENTS; METHOTREXATE; MICE; MICE, NUDE; MICE, SCID; NF-KAPPA B; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TETRADECANOYLPHORBOL ACETATE; TUMOR CELLS, CULTURED;

EID: 64949147925     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E and Ben-Neriah Y: NF-kappaB functions as a tumour promoter in inflammation- associated cancer. Nature 431: 461-466, 2004.
2. Mantovani A: Cancer: inflammation by remote control. Nature 435: 752-753, 2005.
3. Balkwill F and Coussens LM: Cancer: an inflammatory link. Nature 431: 405-406, 2004.
4. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK and Sethi G: Inflammation and cancer: how hot is the link? Biochem Pharmacol 72: 1605-1621, 2006.
5. Ahmed KM, Cao N and Li JJ: HER-2 and NF-kappaB as the targets for therapy-resistant breast cancer. Anticancer Res 26: 4235-4243, 2006.
6. Jin RJ, Lho Y, Connelly L, Wang Y, Yu X, Saint Jean L, Case TC, Ellwood-Yen K, Sawyers CL, Bhowmick NA, Blackwell TS, Yull FE and Matusik RJ: The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen- independent growth. Cancer Res 68: 6762-6769, 2008.
7. Mattson MP and Meffert MK: Roles for NF-kappaB in nerve cell survival, plasticity, and disease. Cell Death Differ 13: 852- 860, 2006.
8. Roman-Bias JA and Jimenez SA: NF-kappaB as a potential therapeutic target in osteoarthritis and rheumatoid arthritis. Osteoarthritis Cartilage 14; 839-848, 2006.
9. Mroz RM, Noparlik J, Chyczewska E, Braszko JJ and Holownia A: Molecular basis of chronic inflammation in lung diseases: new therapeutic approach. J Physiol Pharmacol 58(Suppl 5): 453-460, 2007.
10. Yan Y, Dalmasso G, Nguyen HT, Obertone TS, Charrier- Hisamuddin L, Sitaraman SV and Merlin D: Nuclear factor- kappaB is a critical mediator of Ste20-like proline-/alanine-rich kinase regulation in intestinal inflammation. Am J Pathol 173: 1013-1028, 2008.
11. de Winther MP, Kanters E, Kraal G and Hofker MH: Nuclear factor kappaB signaling in atherogenesis. Arterioscler Thromb Vase Biol 25: 904-914, 2005.
12. Lernbecher T, Muller U and Wirth T: Distinct NF-kappa B/Rel transcription factors are responsible for tissue-specific and inducible gene activation. Nature 365: 767-770, 1993.
13. Schmidt-Ullrich R, Memet S, Lilienbaum A, Feuillard J, Raphael M and Israel A: NF-kappaB activity in transgenic mice: developmental regulation and tissue specificity. Development 122: 2117-2128, 1996.
14. Sizemore N, Leung S and Stark GR: Activation of phosphati- dylinositol 3-kinase in response to interleukin-1 leads to phosphorylation and activation of the NF-kappaB p65/RelA subunit. Mol Cell Biol 19: 4798-4805, 1999.
15. Jenkins DE, Oei Y, Hornig YS, Yu SF, Dusich J, Purchio T and Contag PR: Bioluminescent imaging (BLI) to improve and refine traditional murine models of tumor growth and metastasis. Clin Exp Metastasis 20: 733-744, 2003.
16. Ho TY, Chen YS and Hsiang CY: Noninvasive nuclear factor- kappaB bioluminescence imaging for the assessment of host biomaterial interaction in transgenic mice. Biomaterials 28: 4370-4377, 2007.
17. Sadikot RT and Blackwell TS: Bioluminescence imaging. Proc Am Thorac Soc 2: 537-540, 511-532, 2005.
18. Medicherla S, Li L, Ma JY, Kapoun AM, Gaspar NJ, Liu YW, Mangadu R, O'Young G, Protter AA, Schreiner GF, Wong DH and Higgins LS: Antitumor activity of TGF-beta inhibitor is dependent on the microenvironment. Anticancer Res 27: 4149- 4157, 2007.
19. 18F-fluoro-D-glucose in murine models of breast cancer. Mol Imaging Biol 9: 144-150, 2007.
20. Plathow C and Weber WA: Tumor cell metabolism imaging. J Nucl Med 49(Suppl 2): 43S-63S, 2008.
21. Riemann B, Schafers KP, Schober O and Schafers M: Small animal PET in preclinical studies: opportunities and challenges. Q J Nucl Med Mol Imaging 52: 215-221, 2008.
22. Taketani Y and Oka T: Tumor promoter 12-O-tetradeca- noylphorbol-13- acetate, like epidermal growth factor, stimulates cell proliferation and inhibits differentiation of mouse mammary epithelial cells in culture. Proc Natl Acad Sci USA 80: 1646- 1649, 1983.
23. Hsiang CY, Wu SL and Ho TY: Morin inhibits 12-O-tetradeca- noylphorbol-13-acetate-induced hepatocellular transformation via activator protein 1 signaling pathway and cell cycle progression. Biochem Pharmacol 69: 1603-1611, 2005.
24. Iwase Y, Takemura Y, lu-ichi M, MukainakaT, Ichiishi E, Ito C, Furukawa H, Yano M, Tokuda H and Nishino H: Inhibitory effect of flavonoid derivatives on Epstein-Barr virus activation and two-stage carcinogenesis of skin tumors. Cancer Lett 173: 105- 109, 2001.
25. Nissen E, Pauli G and Vollenbroich D: WST-1 assay - a simple colorimetric method for virus titration. In Vitro Cell Dev Biol Animl?: 28-29, 1997.
26. Chang CH, Wang HE, Wu SY, Fan KH, Tsai TH, Lee TW, Chang SR, Liu RS, Chen CF, Chen CH and Fu YK: Comparative evaluation of FET and FDG for differentiating lung carcinoma from inflammation in mice. Anticancer Res 26: 917-925, 2006.
27. Majumdar S and Aggarwal BB: Methotrexate suppresses NF- kappaB activation through inhibition of IkappaBalpha phosphorylation and degradation. J Immunol 167: 2911-2920, 2001.
28. Lobo ED and Balthasar JP: Pharmacokinetic-pharmacodynamic modeling of methotrexate-induced toxicity in mice. J Pharm Sci 92: 1654-1664, 2003.
29. Apisarnthanarax S, Alauddin MM, Mourtada F, Ariga H, Raju U, Mawlawi O, Han D, Bornmann WG, Ajani JA, Milas L, Gelovani JG and Chao KS: Early detection of chemoradioresponse in esophageal carcinoma by 3'-deoxy-3'-3H-fluorothymidine using preclinical tumor models. Clin Cancer Res 12: 4590-4597, 2006.
30. Wu JC, Inubushi M, Sundaresan G, Schelbert HR and Gambhir SS: Optical imaging of cardiac reporter gene expression in living rats. Circulation 105: 1631-1634, 2002.
31. Rudin M and Weissleder R: Molecular imaging in drug discovery and development. Nat Rev Drug Discov 2: 123-131, 2003.
32. Minn AJ, Kang Y, Serganova I, Gupta GP, Giri DD, Doubrovin M, Ponomarev V, Gerald WL, Blasberg R and Massague J: Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest 115: 44-55, 2005.
33. Stathopoulos GT, Zhu Z, Everhart MB, Kalomenidis I, Lawson WE, Bilaceroglu S, Peterson TE, Mitchell D, Yull FE, Light RW and Blackwell TS: Nuclear factor-kappaB affects tumor progression in a mouse model of malignant pleural effusion. Am J Respir Cell Mol Biol 34: 142-150, 2006.